DWRX1010 (Colonoscopy Bowel Preparation Drug)
Product Description
Daewoong Pharmaceutical Co.,Ltd
-
KR
-
2015On CPHI since
-
1000 - 4999Employees
Company types
Primary activities
Categories
Daewoong Pharmaceutical Co.,Ltd
-
KR
-
2015On CPHI since
-
1000 - 4999Employees
Company types
Primary activities
More Products from Daewoong Pharmaceutical Co.,Ltd (8)
-
Product NABOTA®
Botulinum toxin type A
Indication: Glabella Lines (Approved in KR, US, CA, EU), Post Stroke Upper Limb Spasticity, Crow's feet, Blepharospasm, Benign Masseteric Hypertrophy (Approved in KR)
- Nabota is the only 900kDa Neurotoxin approved in the US and EU since Botox.- It has demonstra... -
Product CLOPAM(Microneedle Patch)
Microneedle is the most active and evolved form of transdermal drug delivery. Its formulation utilizes micro-sized (usually under 1mm in length) needles to deliver drugs past the stratum corneum. CLOPAM is Daewoong Therapeutics' exclusive and patented manufacturing technology that ensures efficient drug ... -
Product ENVLO®
Envlo (Enavogliflozin) is a best-in-class SGLT2 inhibitor for T2DM.
Highlights of Envlo are:
* Launched in Korea from May 2023
* Approved by Korea MFDS in 2022 for T2DM
* T2DM Phase III was completed in Korea as a monotherapy and in combinations with other anti-diabetics (du... -
Product FEXUCLUE®
Fexuclue (Fexuprazan) is the best-in-class novel anti acid secretion agent with rapid onset time and potent acid suppressive effect, addressing the growing unmet needs of PPIs
Highlights of Fexuclue are: * Launched in Korea (2022) and Philippines (2023)
* Approved in Chile and Ecuador qq... -
Product Luphere Depot
Luphere Depot (Leuprorelin) is a generic specialty drug of Lupron/Leuplin. Luphere Depot is a marketed product in Korea since January 2005. Currently, Luphere Depot is under development for US and Japan.
Key Features:
1) Mode of action: GnRH Agonist
2... -
Product Luphere Depot_3.75mg-Inj.
Leuprorelin Acetate
Indication: Prostate cancer, Endometriosis, Pre-menopausal breast cancer, Uterine leiomyomata (Fibroids), Central Precocious Puberty
- Luphere has two formulations; Daewoong*s proprietary patented spray-drying formulation and the emulsion formulation which will make... -
Product Olostar 20/10mg and 40/20mg - Tab.
Olmesartan medoxomil, Rosuvastatin
Indication: Concomitant Hypertension and Dyslipidemia
<World's 1st fixed dose combination of olmesartan and rosuvastatin>
1. Developed with Daewoong's patented formulation technology
2. Indicated for the treatment of both hypertensio... -
Product URSA
25, 50, 100, 200, 250, 300mg - Tab., Soft Cap., Hard Cap.
UDCA (Ursodeoxycholic Acid)
Indication:
Cholestasis(include PBC, PSC), Viral hepatitis C, Gallstone
URSA improves liver function in chronic hepatitis patients, improves symptom and histopathology in Cholestatis...
Daewoong Pharmaceutical Co.,Ltd resources (3)
-
Brochure Daewoong Bio Bioplant Promotion Brochure
It contains an overall introduction to Daewoong Bio's bio plant's milestones, manufacturing facilities, and production capacity. -
Video DAEWOONG PR VIDEO (EN)
We continue to take the initiative by making bold challenges and investments in R&D to leap forward as a global healthcare group. Following the 2022 launch of Fexuclue, a drug treating gastroesophageal reflux disease, the company released Envlo, a Type 2 diabetes treatment. By bolstering its R&D pipeline, Daewoong Pharmaceutical is developing first-in-class and best-in-class drugs.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance